Filtered By:
Condition: Heart Valve Disease
Procedure: Heart Valve Surgery
This page shows you your search results in order of date. This is page number 10.
Order by Relevance | Date
Total 376 results found since Jan 2013.
Comparative Surgical Outcomes of Prosthetic and Native Valve Endocarditis
CONCLUSIONS: PVE carried significant perioperative risks, and was an independent risk factor of overall mortality.PMID:34085423 | PMC:PMC8176072 | DOI:10.4070/kcj.2020.0448
Source: Korean Circulation Journal - June 4, 2021 Category: Cardiology Authors: Won Kyung Pyo Ho Jin Kim Joon Bum Kim Sung Ho Jung Suk Jung Choo Cheol Hyun Chung Jae Won Lee Source Type: research
Late-Breaking Data at ACC.21 Show XARELTO ® (rivaroxaban) Plus Aspirin Significantly Reduced Total Ischemic Events in Peripheral Artery Disease (PAD) Patients After Lower-Extremity Revascularization
RARITAN, N.J., May 16, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today presented new data from the Phase 3 VOYAGER PAD study which showed XARELTO® (rivaroxaban) (2.5 mg twice daily) in combination with aspirin (100 mg once daily) consistently reduced severe vascular events in patients with peripheral artery disease (PAD) after lower-extremity revascularization (LER) compared to aspirin alone regardless of whether it was the first, second, third, or subsequent event. The primary results of VOYAGER PAD showed that XARELTO® plus aspirin reduced first events by 15 percent among patients with PAD ...
Source: Johnson and Johnson - May 16, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
